16.82
price down icon4.81%   -0.85
after-market After Hours: 17.74 0.92 +5.47%
loading
Cadrenal Therapeutics Inc stock is traded at $16.82, with a volume of 24,085. It is down -4.81% in the last 24 hours and down -3.33% over the past month.
See More
Previous Close:
$17.67
Open:
$16.85
24h Volume:
24,085
Relative Volume:
0.57
Market Cap:
$31.62M
Revenue:
-
Net Income/Loss:
$-4.85M
P/E Ratio:
-54.26
EPS:
-0.31
Net Cash Flow:
$-3.95M
1W Performance:
-10.10%
1M Performance:
-3.33%
6M Performance:
+47.54%
1Y Performance:
+87.51%
1-Day Range:
Value
$16.59
$17.97
1-Week Range:
Value
$16.15
$19.03
52-Week Range:
Value
$5.40
$22.90

Cadrenal Therapeutics Inc Stock (CVKD) Company Profile

Name
Name
Cadrenal Therapeutics Inc
Name
Phone
904-300-0701
Name
Address
822 A1A NORTH, PONTE VEDRA
Name
Employee
0
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
CVKD's Discussions on Twitter

Compare CVKD with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CVKD
Cadrenal Therapeutics Inc
16.82 31.62M 0 -4.85M -3.95M -0.31
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.01 124.29B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.64 68.39B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
590.06 35.99B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
262.16 33.93B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
264.32 28.47B 3.81B -644.79M -669.77M -6.24

Cadrenal Therapeutics Inc Stock (CVKD) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-18-23 Initiated Noble Capital Markets Outperform

Cadrenal Therapeutics Inc Stock (CVKD) Latest News

pulisher
08:00 AM

Cadrenal Takes Center Stage: Key Executives to Showcase Novel Anticoagulant at Industry-Leading Events - Stock Titan

08:00 AM
pulisher
01:27 AM

Q1 Earnings Estimate for CVKD Issued By Zacks Small Cap - Defense World

01:27 AM
pulisher
Mar 16, 2025

(CVKD) Trading Advice - Stock Traders Daily

Mar 16, 2025
pulisher
Mar 14, 2025

Altimmune to put its incretin into addiction trials; Tarsus aims to raise $125M - Endpoints News

Mar 14, 2025
pulisher
Mar 14, 2025

Cadrenal Therapeutics Advances Tecarfarin Development in 2024 - TipRanks

Mar 14, 2025
pulisher
Mar 13, 2025

Cadrenal Therapeutics Reports Full Year 2024 Results - TradingView

Mar 13, 2025
pulisher
Mar 13, 2025

Cadrenal Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 13, 2025
pulisher
Mar 13, 2025

Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin - Bluefield Daily Telegraph

Mar 13, 2025
pulisher
Mar 13, 2025

Cadrenal Secures FDA Orphan Drug Status and Abbott Partnership for Breakthrough Phase 3 Trial - StockTitan

Mar 13, 2025
pulisher
Mar 07, 2025

CVKD: Collaborating with Abbott for Pivotal Phase 3 Trial - Research Tree

Mar 07, 2025
pulisher
Mar 05, 2025

(CVKD) Technical Pivots with Risk Controls - Stock Traders Daily

Mar 05, 2025
pulisher
Mar 05, 2025

Cadrenal and Abbott sign agreement for LVAD trial of tecarfarin - Yahoo Finance

Mar 05, 2025
pulisher
Mar 04, 2025

Cadrenal Therapeutics teams with Abbott inTECH-LVAD trial - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

Abbott Laboratories (NYSE:ABT) Partners With Cadrenal Therapeutics For TECH-LVAD Trial In Growing US$2B LVAD Market - Yahoo Finance

Mar 04, 2025
pulisher
Mar 04, 2025

Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD - BioSpace

Mar 04, 2025
pulisher
Mar 04, 2025

Cadrenal Therapeutics to Collaborate With Abbott on Trial of Heart Device Drug -March 04, 2025 at 08:53 am EST - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Cadrenal Therapeutics Announces Collaboration Agreement With Abbott -March 04, 2025 at 08:14 am EST - Marketscreener.com

Mar 04, 2025
pulisher
Mar 03, 2025

Cadrenal Therapeutics (CVKD) Projected to Post Earnings on Monday - The AM Reporter

Mar 03, 2025
pulisher
Mar 03, 2025

Cadrenal Therapeutics (CVKD) Expected to Announce Earnings on Monday - Defense World

Mar 03, 2025
pulisher
Feb 26, 2025

CVKD stock hits 52-week high at $20.79 amid robust growth By Investing.com - Investing.com South Africa

Feb 26, 2025
pulisher
Feb 26, 2025

CVKD stock hits 52-week high at $20.79 amid robust growth - Investing.com India

Feb 26, 2025
pulisher
Feb 22, 2025

(CVKD) Trading Signals - Stock Traders Daily

Feb 22, 2025
pulisher
Feb 08, 2025

Cadrenal Therapeutics Announces New Chief Medical Officer in Recent SEC Filing - Defense World

Feb 08, 2025
pulisher
Feb 07, 2025

Biondi becomes managing partner at Flagship - BioCentury

Feb 07, 2025
pulisher
Feb 07, 2025

Cadrenal Therapeutics Appoints New Chief Medical Officer - TipRanks

Feb 07, 2025
pulisher
Feb 07, 2025

Clinical Trials News Live Feed - StockTitan

Feb 07, 2025
pulisher
Feb 06, 2025

Cadrenal Therapeutics appoints new chief medical officer - MSN

Feb 06, 2025
pulisher
Feb 06, 2025

Cadrenal Therapeutics appoints new chief medical officer By Investing.com - Investing.com UK

Feb 06, 2025
pulisher
Feb 06, 2025

Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin - Business Wire

Feb 06, 2025
pulisher
Feb 06, 2025

Former Amgen & AstraZeneca Executive Takes Helm of Revolutionary Anticoagulation Drug Development - Stock Titan

Feb 06, 2025
pulisher
Feb 05, 2025

Cadrenal Therapeutics to Present at BIO CEO & Investor Conference - BioSpace

Feb 05, 2025
pulisher
Feb 05, 2025

Revolutionary Warfarin Alternative Takes Center Stage: Cadrenal CEO to Unveil Latest Tecarfarin Data - StockTitan

Feb 05, 2025
pulisher
Jan 31, 2025

(CVKD) Investment Report - Stock Traders Daily

Jan 31, 2025
pulisher
Jan 23, 2025

Cadrenal Therapeutics (NASDAQ:CVKD) Trading 14.3% Higher – Time to Buy? - Defense World

Jan 23, 2025
pulisher
Jan 21, 2025

Ponte Vedra-based Cadrenal CEO Quang Pham talks biotech, funding - The Business Journals

Jan 21, 2025
pulisher
Jan 21, 2025

Learn to Evaluate (CVKD) using the Charts - Stock Traders Daily

Jan 21, 2025
pulisher
Jan 13, 2025

Ponte Vedra biotech firm opens the Nasdaq - The Business Journals

Jan 13, 2025
pulisher
Jan 10, 2025

(CVKD) Long Term Investment Analysis - Stock Traders Daily

Jan 10, 2025
pulisher
Jan 09, 2025

Cadrenal Therapeutics CEO to Present Breakthrough Anticoagulant at Lytham Healthcare Summit - StockTitan

Jan 09, 2025
pulisher
Jan 09, 2025

Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 - BioSpace

Jan 09, 2025
pulisher
Jan 03, 2025

Short Interest in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Expands By 5.7% - Defense World

Jan 03, 2025
pulisher
Dec 31, 2024

Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications - Business Wire

Dec 31, 2024
pulisher
Dec 22, 2024

AT&T (NYSE:T) Price Target Raised to $30.00 - Defense World

Dec 22, 2024
pulisher
Dec 21, 2024

Cadrenal Therapeutics (NASDAQ:CVKD) Shares Up 11.6% – Time to Buy? - Defense World

Dec 21, 2024
pulisher
Dec 20, 2024

Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility - The Eastern Progress Online

Dec 20, 2024
pulisher
Dec 18, 2024

CVKDCadrenal Therape Latest Stock News & Market Updates - StockTitan

Dec 18, 2024
pulisher
Dec 18, 2024

Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings - Business Wire

Dec 18, 2024
pulisher
Dec 18, 2024

Cadrenal Therapeutics to Showcase Novel Anticoagulant Tecarfarin at J.P. Morgan Healthcare Conference - Stock Titan

Dec 18, 2024
pulisher
Dec 09, 2024

(CVKD) Trading Report - Stock Traders Daily

Dec 09, 2024
pulisher
Nov 23, 2024

What is Zacks Small Cap’s Estimate for CVKD FY2024 Earnings? - Defense World

Nov 23, 2024

Cadrenal Therapeutics Inc Stock (CVKD) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
Cap:     |  Volume (24h):